3D printed polymeric drug-eluting implants

An extrusion-based 3D printer has been used for the manufacturing of sustained drug release poly(epsilon-caprolactone) (PCL) implants. Such implants can address issues of reduced patient compliance due to the necessary frequent administration of conventional drug delivery systems, such as tablets, capsules and solutions. The selected model drug for this study was lidocaine. Polycaprolactone core-shell implants, as well as polymeric implants with no barrier shell were printed with different drug loading, without the addition of solvents or further excipients. Scanning Electron Microscopy (SEM) analysis revealed the structural integrity of the printed formulations, while Differential Scanning Calorimetry (DSC), X-Ray Diffraction (XRD) and Attenuated Total Reflectance Fourier Transform Infrared spectroscopy (ATR-FTIR) were used to detect potential chemical interactions or modifications. Raman spectroscopy was also used to study material distribution in the prints. The drug release rate of the differently printed formulations was evaluated using a USP4 flow-through cell apparatus. All printed implants demonstrated sustained lidocaine release and the effectiveness of the PCL barrier in this regard. The Korsmeyer-Peppas model was suggested as the best fit to drug release profiles for all the produced implants. This work demonstrates that hot-melt extrusion-based 3D printing is a robust and promising technology for the production of personalisable drug-eluting implants.

Automated summary

Extrusion-based 3D printing was used to manufacture sustained drug release PCL implants. Different drug loading formulations were printed without solvents or excipients, and analyzed using SEM, DSC, XRD, ATR-FTIR, and Raman spectroscopy. The implants demonstrated sustained drug release efficiency and the Korsmeyer-Peppas model was suggested as the best fit for drug release profiles. This work highlights the potential of hot-melt extrusion-based 3D printing for customizable drug-eluting implants.